Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independent mechanisms. [electronic resource]
- International journal of oncology Aug 2005
- 553-61 p. digital
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
1019-6439
Antineoplastic Agents--pharmacology Apoptosis--drug effects Breast Neoplasms--metabolism Camptothecin--analogs & derivatives Caspase 3 Caspase Inhibitors Caspases--metabolism Cell Cycle--drug effects Cell Line, Tumor Cell Proliferation--drug effects Colorectal Neoplasms--metabolism Cysteine Proteinase Inhibitors--pharmacology DNA Topoisomerases, Type I--metabolism Dose-Response Relationship, Drug Drug Synergism Enzyme Inhibitors--pharmacology Fluorouracil--pharmacology Folic Acid Antagonists--pharmacology Glutamates--pharmacology Guanine--analogs & derivatives HT29 Cells Humans Intracellular Signaling Peptides and Proteins Irinotecan Oligopeptides--pharmacology Organoplatinum Compounds--pharmacology Oxaliplatin Pemetrexed Protein Serine-Threonine Kinases--metabolism Quinazolines--pharmacology Thymidylate Synthase--antagonists & inhibitors Time Factors Topoisomerase I Inhibitors rho-Associated Kinases